MedTrace Logo

Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients

NCT00352807 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2007-10-17

No results posted yet for this study

Summary

The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.Study hypothesis: The aqueous humor concentration 45 minutes following dosing of 0.1% Brimonidine Purite™ (pH 7.8) is comparable with 0.15% Brimonidine Purite® (pH 7.2)

Conditions

  • Cataract

Interventions

DRUG

Brimonidine Purite

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Louis B Cantor, MD · IUPUI/Clarian

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352807 on ClinicalTrials.gov